Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hUC-MSC-sEV-002
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Qingdao University
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
hUC-MSC-sEV-002 is an investigational exosome-based therapy consisting of small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stem cells (hUC-MSCs). Developed by The Affiliated Hospital of Qingdao University, it is administered via nebulization for the treatment of moderate to severe allergic rhinitis complicated by asthma. The therapy leverages the immunomodulatory and anti-inflammatory properties of MSC-derived vesicles, which contain bioactive molecules such as proteins, lipids, and RNAs. These components are intended to modulate the airway immune microenvironment, potentially reducing Type 2 (Th2) mediated inflammation and airway hyperresponsiveness in patients who are suboptimally controlled by standard antiallergic therapies.
- Other names
- hUC-MSC-sEV-002 nebulizerhUC-MSC-sEV002 nebulizerhUC-MSC-sEV 002 nebulizerhuman umbilical cord mesenchymal stem cell-derived small extracellular vesicles
Beyond the preview
Go deeper on hUC-MSC-sEV-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hUC-MSC-sEV-002.